Metopiron

Metyrapone, the active ingredient in Metopiron, is a cortisol synthesis inhibitor presented as an oral tablet for oral use. It is used to manage Cushing's syndrome and to aid diagnostic testing of adrenal insufficiency.

GNH USA supplies Metopiron as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metyrapone acts on adrenal steroid synthesis pathways and is employed in specific endocrine conditions. - Cushing's syndrome: reduces excess cortisol production to improve clinical symptoms. - Diagnostic testing of adrenal insufficiency: blocks cortisol synthesis to evaluate adrenal reserve. - Hypercortisolism evaluation: assists clinicians in confirming endogenous excess cortisol levels.

Metyrapone may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: transient light‑headedness, especially on standing. - Headache: occasional tension‑type headache. - Fatigue: feeling of reduced energy or tiredness.

Serious or Rare Side Effects: - Adrenal insufficiency: severe cortisol deficiency requiring urgent medical attention. - Hyponatremia: low blood sodium levels that may cause confusion or seizures. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hypotension: marked drop in blood pressure leading to fainting. - Hypoglycemia: low blood glucose, particularly in patients with diabetes.

Use of Metopiron requires careful clinical monitoring and patient counseling. - Monitor cortisol levels: assess hormonal response after initiation. - Assess electrolytes: watch for sodium and potassium disturbances. - Use cautiously in hepatic impairment: metabolism may be altered. - Avoid abrupt discontinuation: taper to prevent adrenal crisis. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store at room temperature: keep in the original pack, protect from moisture.

Metyrapone can affect and be affected by other medicines; some combinations should be avoided while others need close observation.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition may increase metyrapone levels. - Rifampin: potent CYP inducer can reduce efficacy of metyrapone. - Exogenous glucocorticoids: may counteract the intended cortisol‑lowering effect.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may influence adrenal hormone balance. - Antihypertensives: blood pressure changes may be accentuated. - Diuretics: electrolyte shifts can be amplified, requiring monitoring.